These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 25595685)

  • 21. Synthesis and antiviral activity of new phenylimidazopyridines and N-benzylidenequinolinamines derived by molecular simplification of phenylimidazo[4,5-g]quinolines.
    Loddo R; Briguglio I; Corona P; Piras S; Loriga M; Paglietti G; Carta A; Sanna G; Giliberti G; Ibba C; Farci P; La Colla P
    Eur J Med Chem; 2014 Sep; 84():8-16. PubMed ID: 25014745
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Substituted N-(4-amino-2-chlorophenyl)-5-chloro-2-hydroxybenzamide analogues potently inhibit respiratory syncytial virus (RSV) replication and RSV infection-associated inflammatory responses.
    Xu J; Wu W; Chen H; Xue Y; Bao X; Zhou J
    Bioorg Med Chem; 2021 Jun; 39():116157. PubMed ID: 33895704
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.
    Wu H; Pfarr DS; Johnson S; Brewah YA; Woods RM; Patel NK; White WI; Young JF; Kiener PA
    J Mol Biol; 2007 May; 368(3):652-65. PubMed ID: 17362988
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 1,4-Benzodiazepines as inhibitors of respiratory syncytial virus.
    Carter MC; Alber DG; Baxter RC; Bithell SK; Budworth J; Chubb A; Cockerill GS; Dowdell VC; Henderson EA; Keegan SJ; Kelsey RD; Lockyer MJ; Stables JN; Wilson LJ; Powell KL
    J Med Chem; 2006 Apr; 49(7):2311-9. PubMed ID: 16570927
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of β-D-2'-deoxy-2'-α-fluoro-4'-α-cyano-5-aza-7,9-dideaza adenosine as a potent nucleoside inhibitor of respiratory syncytial virus with excellent selectivity over mitochondrial RNA and DNA polymerases.
    Clarke MO; Mackman R; Byun D; Hui H; Barauskas O; Birkus G; Chun BK; Doerffler E; Feng J; Karki K; Lee G; Perron M; Siegel D; Swaminathan S; Lee W
    Bioorg Med Chem Lett; 2015 Jun; 25(12):2484-7. PubMed ID: 25978965
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel inhibitor of respiratory syncytial virus isolated from ethnobotanicals.
    Ojwang JO; Wang YH; Wyde PR; Fischer NH; Schuehly W; Appleman JR; Hinds S; Shimasaki CD
    Antiviral Res; 2005 Dec; 68(3):163-72. PubMed ID: 16280176
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An update on respiratory syncytial virus antiviral agents.
    Prince GA
    Expert Opin Investig Drugs; 2001 Feb; 10(2):297-308. PubMed ID: 11178342
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potent inhibition of respiratory syncytial virus by combination treatment with 2-5A antisense and ribavirin.
    Xu Z; Kuang M; Okicki JR; Cramer H; Chaudhary N
    Antiviral Res; 2004 Mar; 61(3):195-206. PubMed ID: 15168801
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A respiratory syncytial virus isolate enables the testing of virucidal products.
    Thevenin T; Lobert PE; Dewilde A; Hober D
    Int J Hyg Environ Health; 2012 Apr; 215(3):293-6. PubMed ID: 22079427
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of novel benzothienoazepine derivatives as potent inhibitors of respiratory syncytial virus.
    Fordyce EAF; Brookes DW; Lise-Ciana C; Coates MS; Hunt SF; Ito K; King-Underwood J; Onions ST; Parra GF; Rapeport G; Sherbukhin V; Stockwell JA; Strong P; Thomas JC; Murray J
    Bioorg Med Chem Lett; 2017 May; 27(10):2201-2206. PubMed ID: 28372911
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pyrimidine containing RSV fusion inhibitors.
    Nikitenko A; Raifeld Y; Mitsner B; Newman H
    Bioorg Med Chem Lett; 2005 Jan; 15(2):427-30. PubMed ID: 15603966
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Respiratory syncytial virus fusion inhibitors. Part 7: structure-activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo.
    Sin N; Venables BL; Combrink KD; Gulgeze HB; Yu KL; Civiello RL; Thuring J; Wang XA; Yang Z; Zadjura L; Marino A; Kadow KF; Cianci CW; Clarke J; Genovesi EV; Medina I; Lamb L; Krystal M; Meanwell NA
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4857-62. PubMed ID: 19596574
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lack of effect of bovine lactoferrin in respiratory syncytial virus replication and clinical disease severity in the mouse model.
    Gualdi L; Mertz S; Gomez AM; Ramilo O; Wittke A; Mejias A
    Antiviral Res; 2013 Aug; 99(2):188-95. PubMed ID: 23735300
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of nyasol and structurally related compounds as the active principles from Anemarrhena asphodeloides against respiratory syncytial virus (RSV).
    Bae G; Yu JR; Lee J; Chang J; Seo EK
    Chem Biodivers; 2007 Sep; 4(9):2231-5. PubMed ID: 17886842
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of a potent respiratory syncytial virus RNA polymerase inhibitor.
    Xiong H; Foulk M; Aschenbrenner L; Fan J; Tiong-Yip CL; Johnson KD; Moustakas D; Fleming PR; Brown DG; Zhang M; Ferguson D; Wu D; Yu Q
    Bioorg Med Chem Lett; 2013 Dec; 23(24):6789-93. PubMed ID: 24211022
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Respiratory syncytial virus inhibitors. Part 2: Benzimidazol-2-one derivatives.
    Yu KL; Zhang Y; Civiello RL; Trehan AK; Pearce BC; Yin Z; Combrink KD; Gulgeze HB; Wang XA; Kadow KF; Cianci CW; Krystal M; Meanwell NA
    Bioorg Med Chem Lett; 2004 Mar; 14(5):1133-7. PubMed ID: 14980651
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of norakin on respiratory syncytial virus in tissue culture and in mice.
    Mentel R; Schroeder C; Döhner L
    Acta Virol; 1989 Mar; 33(2):162-6. PubMed ID: 2569812
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121).
    Bonfanti JF; Meyer C; Doublet F; Fortin J; Muller P; Queguiner L; Gevers T; Janssens P; Szel H; Willebrords R; Timmerman P; Wuyts K; van Remoortere P; Janssens F; Wigerinck P; Andries K
    J Med Chem; 2008 Feb; 51(4):875-96. PubMed ID: 18254606
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lovastatin treatment mitigates the pro-inflammatory cytokine response in respiratory syncytial virus infected macrophage cells.
    Ravi LI; Li L; Wong PS; Sutejo R; Tan BH; Sugrue RJ
    Antiviral Res; 2013 May; 98(2):332-43. PubMed ID: 23523944
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New strategies for control of respiratory syncytial virus infection.
    Nokes JD; Cane PA
    Curr Opin Infect Dis; 2008 Dec; 21(6):639-43. PubMed ID: 18978532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.